The purpose of this document is to provide guidance on the cleaning and disinfection of environmental surfaces in the context of COVID-19. This guidance is intended for health care professionals, public health professionals and health authorities that are developing and implementing policies and sta...ndard operating procedures (SOP) on the cleaning and disinfection of environmental surfaces in the context of COVID-19.
more
Framework of Indictors and Targets
Ukrainian Title: ІНСТРУКЦІЯ ДЛЯ ПІДТРИМКИ ІНТЕГРАЦІЇ ФАРМАЦЕВТИЧНИХ ПРАЦІВНИКІВ-БІЖЕНЦІВ З УКРАЇНИ
This information is based on data provided by the All-Ukrainian Pharmaceutical Chamber (AUPC) to the International Pharmaceutic...al Federation (FIP) in 2017, reviewed by Dr Iryna Vlasenko in April 2022. It is provided to support the integration of refugee pharmacists or pharmacy technicians from Ukraine in other countries. Some data may not be entirely up to date, but will be updated as soon as possible. This document was also developed following the recommendations and inputs by the FIP Forum for Pharmacy Professional Regulators and the FIP Workforce Development Hub.
more
Reporting period: January 2014 – December 2014
The human immunodeficiency virus (HIV) epidemic in Myanmar is concentrated among men who have sex with men (MSM), people who inject drugs (PWID) and female sex workers (FSW). HIV prevalence in the adult population aged 15 years and older was esti...mated at 0.54% in 2014. But data from HIV Sentinel Sero-Surveillance (HSS) indicates higher prevalence in 2014 among key populations: FSW 6.3%, MSM 6.6% and PWID 23.1%. Compared to 2012 data, the prevalence has declined from 7.1% in FSW and 8.9% in MSM, but has increased from 18% in PWID.
Epidemiological modelling suggests that in 2014 there were around 212,000 people living with HIV (PLHIV) in Myanmar, 34% of whom were females. Nearly 11,000 people died of HIV-related illnesses, compared to approximately 15,000 in 2011. An estimated 9,000 new infections occurred in 2014.
more
Apruébase la Guía Práctica Clínica Nacional sobre Prevención, Diagnóstico y Tratamiento de la Diabetes Mellitus Tipo 2 - Resulocíon 695/2009 Ministerio de Salud (M.S.)